CASP3 and Familial prostate cancer: Combining Bufalin and Hydroxycamptothecin reduced the cell cycle arrest in G2/M and S phases in human prostate cancer cell line DU145, increasing the expression of caspase-3 and caspase-9 and inhibiting cell proliferation (15).